 |
|
|
|
|
|
|
|
The discovery of angiogenesis inhibitors: A new class of drugs
The Institute for Genomic Research (TIGR)
[http://www.entremed.com]
EntreMed, Inc. is the biopharmaceutical company that licensed the three naturally occurring inhibitors of angiogenesis -- endostatin, angiostatin, and Panzem (2ME2) -- that were discovered in Dr. Folkman's Surgical Research Laboratory in Boston. While several drug companies are developing and testing different types of angiogenesis inhibitors, EntreMed is the only company conducting clinical trials of these naturally occurring drugs. EntreMed has an interesting and well-organized Web site full of information on the progress of their drugs' clinical trials, articles related to anti-angiogenesis and Dr. Folkman, and a listing of helpful links for cancer patients and their families.
Celera Genomics
[http://www.cancer.wisc.edu/]
The two Wisconsin residents who were featured in "Cancer Warrior" while enrolled in the clinical trial of endostatin, received treatment at the University of Wisconsin Comprehensive Cancer Center. The Center, one of 37 National Cancer Institute-designated comprehensive cancer centers in the U.S., is a world leader in cancer research and treatment. Visit the Center's Web site for more information about its clinical trials. Though the endostatin trial is currently closed to new patients, clinical trials are available for other cancer drugs.
J. Craig Venter, Ph.D., statement of testimony
[http://www.childrenshospital.org/]
The pioneering angiogenesis research of Dr. Judah Folkman and his colleagues takes place at the Children's Surgical Research Laboratories at Children's Hospital in Boston, Massachusetts. If you wish to make a donation to support Dr. Folkman's research or want to find out more about the hospital where he works, visit this site.
Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer:
By Robert Cooke. New York: Random House, 2001
Judah Folkman granted veteran science writer Bob Cooke extensive (and exclusive) interviews for this book, which we excerpt in Designing Clinical Trials. It tells the full story of the discovery of angiogenesis and its stimulators and inhibitors, some of which may provide physicians with a new means to battle cancer. View the excerpt on NOVA Online.
A list of cancer resources is also available at NOVA Online.
National Human Genome Research Institute (NHGRI)
[http://www.agingeye.org/seminar/damore0900/index.shtml]
Originally presented in September 2000, Dr. Pat D'Amore, director of the Aging Eye Center at Schepens Eye Research Institute, expands upon a previous seminar on paracrine regulation of vessel growth by discussing the role of cell interactions in growth control and vascular development.
More: The discovery of angiogenesis inhibitors: A new class of drugs
|
|
|
|
|
|
